Stimcare regularly uses the possibilities of a further development; namely on the one hand by the product portfolio extension with new unique technologies – e.g. bioabsorbable coronary stent, and on the other hand also by the cooperation with other renowned manufacturers of a medical technology.
Expected products for 2016 and 2017
NEURO AD SYSTEM™
- Unique non-pharmacologic treatment of Alzheimer Disease(AD) based on unique principle of combination repetitive transcranial magnetic stimulation together with training of cognitive functions
- It’s the only treatment modality with valid CE certificate and clinically proven persistent dramatic improvement versus recent therapy with inhibitors of cholinesterase and Memantine; in addition without its deleterious side effects
- In close cooperation with Neuronix Medical we’re going to perform Clinical Trial for patients with mild-to-moderate Alzheimer disease - as the very first country within European Union – in the National Institute of Mental Health in Klecany as of May 2016
- For all the patients and/or their relatives, who might be interested; please contact for more details: Prof. MUDr. Jiri Horacek, NUDZ, Topolova 748, 250 67 Klecany; tlf. 266 003 370
The representative of the latest generation of fully absorbable, so called bioabsorbable coronary stents.
After fulfilling its role (patency of a coronary artery) it resorbs in the vascular stream spontaneously within a period of 36 - 48 months, which reduces the necessity of long-term supporting dual anticoagulant therapy (aspirin + clopidogrel).
Its advantage is independence of temperature ("non-temperature dependent")
The expected launch in the Czech Republic Q2 2017